Biovica posts 56% Q1 sales growth amid operations streamlining
Biovica delivered 56% sales growth in the first quarter, citing strong Pharma Services momentum, alongside actions to streamline operations and strengthen leadership for its next growth phase.
Story updates
03:52:44 PM UTC
SquawkNews
Q1 saw 56% sales growth, driven by Pharma Services, with significant organizational restructuring and leadership changes. Operating loss widened slightly due to restructuring costs, but liquidity improved, and a SEK 29.2 million rights issue was proposed to support future growth.Original document…
Biovica delivered 56% sales growth in the first quarter, with strong momentum in Pharma Services. The company also said it is taking steps to streamline operations, strengthen leadership and position itself for its next phase of growth. Q1 (May 2026 — July 2026) (comparison figures are for the same period last year).